Mustang Bio, Inc.

Equities

MBIO

US62818Q2030

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.3161 ^USD	-9.79%		-7.46%	-76.59%

Apr. 15	North American Morning Briefing : Stock Futures Rise Despite Middle East Tensions	DJ
Mar. 28	Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	CI

Mustang Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 11, 2024 at 04:02 pm EDT

Mustang Bio, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 51.6 million compared to USD 77.53 million a year ago. Basic loss per share from continuing operations was USD 6 compared to USD 10.09 a year ago.

Latest news about Mustang Bio, Inc.

North American Morning Briefing : Stock Futures Rise Despite Middle East Tensions	Apr. 15	DJ
Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	Mar. 28	CI
Mustang Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma	Mar. 07	CI
Mustang Bio, Inc Appoints James Murphy as Interim Chief Financial Officer	Jan. 25	CI
Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer	Dec. 12	CI
Mustang Bio, Inc. Announces Executive Changes	Dec. 12	CI
Mustang Bio, Inc. Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology Annual Meeting	Dec. 11	CI
Mustang Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Mustang Bio, Inc. announced that it has received $4.742942 million in funding	Nov. 02	CI
Mustang Bio, Inc. Announces Interim Phase 1/2 Data from Mustang's Multicenter Clinical Trial of MB-106	Nov. 02	CI
Mustang Bio Shares Down 12% After Direct Offering Prices	23-10-26	DJ
Mustang Bio to Start Cancer Trial Following FDA Acceptance of IND Application for MB-109; Shares Jump	23-10-26	MT
Mustang Bio Shares Rise 13% After FDA Acceptance of IND Application	23-10-26	DJ
Mustang Bio Gets FDA Acceptance of IND Application for MB-109 Cancer Treatment	23-10-26	DJ
Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-109, A Novel Combination of MB-101 (IL13RA2-Targeted Car-T Cell Therapy) and MB-108 (HSV-1 Oncolytic Virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma	23-10-26	CI
Mustang Bio, Inc. announced that it expects to receive $4.742942 million in funding	23-10-25	CI
Mustang Bio Says Cancer Treatment MB-106 Shows Clinical Response, Committee Approves Increased Dosage	23-08-16	MT
Mustang Bio, Inc. Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy	23-08-16	CI
BTIG Adjusts Price Target on Mustang Bio to $16 From $20, Maintains Buy Rating	23-08-15	MT
Mustang Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
UBriGene Biosciences Inc. completed the acquisition of Worcester manufacturing facility of Mustang Bio, Inc.	23-07-27	CI
Mustang Bio, Inc. Terminates Exclusive License Agreement with Regents of the University of California	23-07-11	CI
BTIG Raises Price Target on Mustang Bio to $20 From $4, Maintains Buy Rating	23-06-16	MT
Mustang Bio Reports Final Results From Follicular Lymphoma Group of Phase 1/2 Clinical Trial	23-06-15	MT

Chart Mustang Bio, Inc.

Duration

Period

More charts

Company Profile

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. It is developing a CAR T therapy for hematologic malignancies in partnership with Fred Hutch targeting CD20 (MB-106). In partnership with St. Jude, its X-linked Severe Combined Immunodeficiency (XSCID) gene therapy programs (MB-117 and MB-217) are being developed under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3161 USD

Average target price

17.5 USD

Spread / Average Target

+5,436.22%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MUSTANG BIO, INC.	-76.59%	3.26M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs